1. Home
  2. WAFU vs ACON Comparison

WAFU vs ACON Comparison

Compare WAFU & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WAFU
  • ACON
  • Stock Information
  • Founded
  • WAFU 1999
  • ACON 2008
  • Country
  • WAFU China
  • ACON United States
  • Employees
  • WAFU N/A
  • ACON N/A
  • Industry
  • WAFU Other Consumer Services
  • ACON Retail: Computer Software & Peripheral Equipment
  • Sector
  • WAFU Real Estate
  • ACON Technology
  • Exchange
  • WAFU Nasdaq
  • ACON Nasdaq
  • Market Cap
  • WAFU N/A
  • ACON 4.8M
  • IPO Year
  • WAFU 2019
  • ACON 2022
  • Fundamental
  • Price
  • WAFU $1.48
  • ACON $6.85
  • Analyst Decision
  • WAFU
  • ACON Buy
  • Analyst Count
  • WAFU 0
  • ACON 2
  • Target Price
  • WAFU N/A
  • ACON $481.00
  • AVG Volume (30 Days)
  • WAFU 40.8K
  • ACON 51.2K
  • Earning Date
  • WAFU 01-01-0001
  • ACON 05-14-2025
  • Dividend Yield
  • WAFU N/A
  • ACON N/A
  • EPS Growth
  • WAFU N/A
  • ACON N/A
  • EPS
  • WAFU N/A
  • ACON N/A
  • Revenue
  • WAFU $6,374,594.00
  • ACON $45,724.00
  • Revenue This Year
  • WAFU N/A
  • ACON $212.31
  • Revenue Next Year
  • WAFU N/A
  • ACON N/A
  • P/E Ratio
  • WAFU N/A
  • ACON N/A
  • Revenue Growth
  • WAFU N/A
  • ACON N/A
  • 52 Week Low
  • WAFU $1.22
  • ACON $6.20
  • 52 Week High
  • WAFU $7.49
  • ACON $3,500.42
  • Technical
  • Relative Strength Index (RSI)
  • WAFU 51.88
  • ACON 33.65
  • Support Level
  • WAFU $1.36
  • ACON $6.20
  • Resistance Level
  • WAFU $1.49
  • ACON $7.54
  • Average True Range (ATR)
  • WAFU 0.09
  • ACON 0.65
  • MACD
  • WAFU 0.02
  • ACON 3.52
  • Stochastic Oscillator
  • WAFU 78.43
  • ACON 23.21

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Share on Social Networks: